ArticleHeart, lung and vessels2015
Use of levosimendan in patients with heart failure in different settings: case reports and treatment guidance.
Article in Heart, lung and vessels, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The inodilator levosimendan in repetitive doses in the treatment of advanced heart failure.European heart journal supplements : journal of the European Society of Cardiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe inodilator levosimendan was developed as a treatment for acutely decompensated severe chronic heart failure. In recent years, its use has broadened to treatment of heart failure in different settings. These include advanced chronic heart failure, and other scenarios where haemodynamic stability is sought, such as pre-operative treatment of patients at risk of low cardiac output syndrome or peri-operative heart failure. The aims of this presentation of four case reports were to compare the use of levosimendan in different settings, and to highlight differences and similarities in the effects obtained, with the purpose of defining common guidance on the use of levosimendan.
methodsWe retrospectively reviewed the records of patients with heart failure in the registries of our wards, identified and described four cases where levosimendan was received in four different settings. We provide here a systematic report on these four cases.
resultsOne patient suffered from acutely worsened chronic heart failure, one from advanced chronic heart failure, with repetitive treatment needed, one experienced acute ventricular failure as a result of a perioperative myocardial infarction, and one with left-ventricular function impairment and planned surgery.
conclusionsHeart failure arising from different aetiologies and occurring in different settings is amenable to successful treatment with levosimendan.
Indexed as
Identifiers
26157740PMC4476768What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.